Results 241 – 250 of 250 for Enhertu (0.05 seconds)

Datopotamab deruxtecan-based combinations show promising clinical activity in patients with advanced non-small cell lung cancer

(gefitinib); Imfinzi (durvalumab) and tremelimumab; Enhertu (trastuzumab deruxtecan) and datopotamab deruxtecan in collaboration with Daiichi Sankyo; ...

Tagrisso plus savolitinib demonstrated 49% objective response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial

(gefitinib); Imfinzi (durvalumab) and tremelimumab; Enhertu (trastuzumab deruxtecan) and datopotamab deruxtecan in collaboration with Daiichi Sankyo; ...

Tagrisso approved in Japan for the adjuvant treatment of patients with early-stage EGFR-mutated lung cancer

(gefitinib); Imfinzi (durvalumab) and tremelimumab; Enhertu (trastuzumab deruxtecan) and datopotamab deruxtecan in collaboration with Daiichi Sankyo; ...

Tagrisso recommended for approval in the EU by CHMP for patients with unresectable EGFR-mutated lung cancer

(gefitinib); Imfinzi (durvalumab) and Imjudo (tremelimumab); Enhertu (trastuzumab deruxtecan) and datopotamab deruxtecan in collaboration with Daiichi ...

Tagrisso approved in the EU for patients with unresectable EGFR-mutated lung cancer

(gefitinib); Imfinzi (durvalumab) and Imjudo (tremelimumab); Enhertu (trastuzumab deruxtecan) and datopotamab deruxtecan in collaboration with Daiichi ...

Imfinzi recommended for approval in the EU by CHMP as first and only immunotherapy for limited-stage small cell lung cancer

(osimertinib) and Iressa (gefitinib); Imfinzi and Imjudo; Enhertu (trastuzumab deruxtecan) and Datroway (datopotamab deruxtecan) in collaboration with ...

Imfinzi approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer

(osimertinib) and Iressa (gefitinib); Imfinzi and Imjudo; Enhertu (trastuzumab deruxtecan) and datopotamab deruxtecan in collaboration with Daiichi ...

Tagrisso plus chemotherapy demonstrated statistically significant and clinically meaningful improvement in overall survival in EGFR-mutated advanced lung cancer

including Tagrisso and Iressa (gefitinib); Imfinzi (durvalumab) and Imjudo (tremelimumab); Enhertu...

Medicines: Portfolio and Pipeline

Enhertu trastuzumab deruxtecan

Imfinzi-based perioperative regimen approved in the EU for resectable non-small cell lung cancer

(osimertinib) and Iressa (gefitinib); Imfinzi and Imjudo; Enhertu (trastuzumab deruxtecan) and Datroway (datopotamab deruxtecan) in collaboration with ...

Previous 15 16 17 18 19 20 21 22 23 24 25 26 Next